Adakveo(crizanlizumab)
Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Adakveo
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adakveo | Biologic Licensing Application | 2024-06-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
crizanlizumab, Adakveo, Novartis Pharmaceuticals Corporation | |||
| 2026-11-15 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0791 | Injection, crizanlizumab-tmca, 5 mg |
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 6 | 2 | 2 | 6 | 16 |
| Covid-19 | D000086382 | — | — | — | 1 | — | 1 | — | 2 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Leukoencephalopathies | D056784 | HP_0002352 | — | — | 1 | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Priapism | D011317 | HP_0200023 | N48.3 | — | 1 | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral infarction | D002544 | — | I63 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Crizanlizumab |
| INN | crizanlizumab |
| Description | Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297734 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15271 |
| UNII ID | L7451S9126 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SELP
SELP
Organism
Homo sapiens
Gene name
SELP
Gene synonyms
GMRP, GRMP
NCBI Gene ID
Protein name
P-selectin
Protein synonyms
CD62 antigen-like family member P, CD62P, GMP-140, Granule membrane protein 140, granule membrane protein 140kDa, granulocyte membrane protein, LECAM3, Leukocyte-endothelial cell adhesion molecule 3, PADGEM, Platelet activation dependent granule-external membrane protein, platelet alpha-granule membrane protein, selectin P (granule membrane protein 140kDa, antigen CD62)
Uniprot ID
Mouse ortholog
Selp (20344)
P-selectin (Q32MF1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Adakveo – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 810 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,156 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use